Nanoparticulate delivery of LHRH analogue for the treatment of prostate cancer

ISSN： 1083-7450

Source： Pharmaceutical Development and Technology, Vol.18, Iss.3, 2013-06, pp. : 645-652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

LHRH-Targeted Drug Delivery Systems for Cancer Therapy

Mini Reviews in Medicinal Chemistry, Vol. 17, Iss. 3, 2017-01 ,pp. : 258-267

Bentham Science Publishers

Access to resources Recommend Favorite

Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer

By Tsintavis Athanassios Lambou Theocharis Vacalicos John Koutsilieris Michael Karamanolakis Dimitrios Bogdanos John Milathianakis Constantine Mitsiades Constantine Dimopoulos Theodoros

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 2, 2002-02 ,pp. : 283-293

Informa Healthcare

Access to resources Recommend Favorite

Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer

Current Drug Delivery, Vol. 9, Iss. 2, 2012-03 ,pp. : 122-131

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer

Current Drug Targets, Vol. 17, Iss. 5, 2016-04 ,pp. : 488-494

Bentham Science Publishers

Access to resources Recommend Favorite

Adjuvant Luteinising Hormone-Releasing Hormone (LHRH)--Agonist Therapy in Prostate Cancer

By Kaisary A.V. Jarmulowicz M.

UroOncology, Vol. 3, Iss. 2, 2003-06 ,pp. : 51-62

Ashgate Publishing Ltd

Access to resources Recommend Favorite